05:51 AM EDT, 10/17/2025 (MT Newswires) -- Novo Nordisk ( NVO ) shares were down 4.1% in recent premarket activity Friday after US President Donald Trump reportedly vowed to reduce the price of the comapny's Ozempic weight-loss drug.

Ozempic's price would be "much lower" once the Trump administration finalizes negotiations with Novo Nordisk ( NVO ), the Financial Times reported, citing Trump's remarks at a Thursday press conference.

The company didn't immediately respond to MT Newswires' request for comment.

Eli Lilly ( LLY ) shares were down 4.4%.